Vasculitis & polymyalgia rheumatica
The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial
Authors' conclusion
Patients with ANCA-associated vasculitis who received avacopan reported statistically significant and clinically meaningful improvements in health-related quality of life at 26 and 52 weeks and in health utility EQ-5D and SF-6D scores at 52 weeks.
Study context
- Population
- Patients with newly diagnosed or relapsing AAV
- Participants
- 331 patients
- Comparison
- Avacopan vs prednisone taper
- Avacopann = 166
- Prednisonen = 165reference
- Primary endpoint
- Health-related quality of life: SF-36 v2 summary and domain scores, EQ-5D-5L and EQ-5D health utility; SF-6D health utility
- Follow-up
- Weeks 26 and 52
Methodological detailsphase 3, double-blind, double-dummy, modified intention-to-treat population
- Phase 3
- Double-blind
- Double-dummy
- Modified intention-to-treat population
Primary result
As reported in the abstract
SF-36 physical component summary, LS mean difference from baseline
- Significantly greater in Avacopan than Prednisone at weeks 26 and 52
- Significantly greater in Avacopan in five of eight SF-36 domains at week 26 and two of eight at week 52
- Modified intention-to-treat population
Further findings
Proportion with scores ≥ normative values, SF-36 domains · weeks 26 and 52
- Higher in Avacopan across all SF-36 domains; not statistically significant except role physical and vitality domains at week 26
LS mean change from baseline in EQ-5D-5L VAS, EQ-5D and SF-6D health utility scores · up to week 52
- Significantly greater in Avacopan than Prednisone
Median total prednisone up to week 52
- ≈2500 mg less in Avacopan
Original publication
The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial. Lancet Rheumatol. Published 24 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →